Global Nuclear Medicine/Radiopharmaceuticals Market, 2018-2024: Increase In Research Activities - Pharmaceuticals And Biotechnology Sectors

News provided by

Jul 18, 2018, 09:00 ET

DUBLIN, July 18, 2018 /PRNewswire/ --

The "Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The global nuclear medicine/radiopharmaceutical market is expected to reach $9,275.3 million by 2022

Over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide's and radiolabeled compounds. This advancement has majorly impacted the health care practice. In the present scenario nuclear medicine is considered to be one of the diagnostics and therapeutic modality technique for probing, tracking and treating disease-related tissue function, progression and treatment response.

Non-invasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of target-specific radiotracers in tissue.

Radioisotopes are used in a wide variety of applications like oncology, cardiovascular and neurological disorders. But in recent times, advancements in the field of nuclear medicine and radioactive tracers have emerged to provide few practical methods for studying the limited metabolic activities of bones and teeth, hence has found a role in dental science research.

Nuclear medicinal market is mainly classified into type (diagnosis & therapeutics), application and end-users. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.

The nuclear medicine/radiopharmaceuticals market is expected to grow at single digit CAGR during 2015 to 2022. The factors driving the growth of this market are increased application of radiopharmaceuticals, rise in public awareness, usage of hybrid imaging, abundance of radio pharmaceuticals, technological advancements; alpha radio immunotherapy based targeted cancer treatment and wide range of available products likely to propel the nuclear medicine market.

In addition to this, increasing need in emerging markets, production of radio pharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes, increasing therapeutic application areas and replacement of old/traditional equipment are some of the opportunities that are propelling the growth of the market. However, regulatory issues, high cost and supply shortage of isotopes, shorter half life of radiopharmaceuticals, and threat from traditional/alternative diagnostic procedures are hampering the growth of the market.

The threats for the nuclear medicine/radiopharmaceuticals market include huge capital investment and shortage of qualified technicians. The major problem area of nuclear medicine market is closure of reactors.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Take Aways
2.2 Report Scope
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Increased Applications Of Radiopharmaceuticals
3.3.1.2 Rise In Public Awareness
3.3.1.3 Usage Of Hybrid Imaging
3.3.1.4 Technological Advancements
3.3.1.5 Increasing Needs In Emerging Markets
3.3.1.6 Production Of Radiopharmaceuticals From Cyclotrons
3.3.1.7 Efficient Diagnosis And Treatments
3.3.2 Restraints And Threats
3.3.2.1 Shorter Half-Life Of Radiopharmaceuticals
3.3.2.2 High Cost And Supply Shortage Of Isotopes
3.3.2.3 Radio Toxicity
3.3.2.4 Shortage Of Qualified Technicians
3.3.2.5 Regulatory Issues
3.3.2.6 Threat From Traditional/Alternative Diagnostic Procedures
3.3.2.7 Huge Capital Investment
3.4 Problem Areas
3.4.1 Closure Of Reactors
3.5 Winning Imperatives
3.5.1 Availability Of Technetium
3.6 Regulatory Guidelines
3.7 Reimbursement Scenario And Challenges
3.8 Clinical Trials
3.9 Patent Trends
3.10 Supply Chain Analysis
3.10.1 Reactors
3.10.2 Processing Facility
3.10.3 Generators Manufacturing Units
3.10.4 Hospitals And Central Radio Pharmacies
3.11 List Of Potential New Reactors
3.12 List Of FDA Approved Radiopharmaceuticals
3.13 Porter's Five Force Analysis
3.13.1 Threat Of New Entrants
3.13.2 Threat Of Substitutes
3.13.3 Bargaining Power Of Suppliers
3.13.4 Bargaining Power Of Buyers
3.13.5 Competitive Rivalry
3.14 Market Share Analysis By Major Players
3.14.1 Nuclear Medicine Market
3.14.2 Spect Market
3.14.3 Pet Market
3.14.4 Tc-99 Market

4 Nuclear Medicine Global Market, By Modality
4.1 Introduction
4.2 Diagnostics
4.2.1 Radiopharmaceuticals For Diagnosis, By Isotopes
4.2.1.1 Spect, By Isotopes
4.2.1.1.1 Technetium (Tc-99M)
4.2.1.1.2 Thallium (Tl-201)
4.2.1.1.3 Gallium (Ga-67)
4.2.1.1.4 Iodine (I-123)
4.2.1.1.5 Samarium (Sm-153)
4.2.1.1.6 Yttrium (Y-90)
4.2.1.1.7 Rhenium (Re-186)
4.2.1.1.8 Others
4.2.1.2 Pet, By Isotopes
4.2.1.2.1 Fluorodeoxyglucose (18F-Fdg)
4.2.1.2.2 Gallium (Ga-68)
4.2.1.2.3 Rubidium (Rb-82)
4.2.1.2.4 Others
4.2.2 Nuclear Medicine For Diagnosis, By Application
4.2.2.1 Spect By Application
4.2.2.1.1 Cardiology
4.2.2.1.2 Pulmonary
4.2.2.1.3 Oncology
4.2.2.1.4 Nephrology
4.2.2.1.5 Neurology
4.2.2.1.6 Inflammation
4.2.2.1.7 Thyroid Glands
4.2.2.1.8 Lymphology
4.2.2.1.9 Others
4.2.2.2 Pet By Application
4.2.2.2.1 Oncology
4.2.2.2.2 Neurology
4.2.2.2.3 Cardiology
4.2.2.2.4 Inflammation
4.2.2.2.5 Others
4.3 Therapeutics
4.3.1 Nuclear Medicine For Therapeutics, By Radiation Type
4.3.1.1 Beta Radiation Therapy
4.3.1.1.1 Yttrium (Y-90)
4.3.1.1.2 Iodine (I-131)
4.3.1.1.3 Lutetium (Lu-177)
4.3.1.1.4 Samarium (Sm-153)
4.3.1.1.5 Rhenium (Re-186)
4.3.1.1.6 Strontium (Sr-89)
4.3.1.1.7 Erbium (Er-169)
4.3.1.1.8 Others
4.3.1.2 Alpha Radiation Therapy, By Isotopes
4.3.1.3 Brachytherapy, By Isotopes
4.3.1.3.1 Iodine (I-125)
4.3.1.3.2 Cesium (Cs-131)
4.3.1.3.3 Iridium (Ir-192)
4.3.1.3.4 Palladium (Pd-103)
4.3.1.3.5 Others
4.3.2 Nuclear Medicine Therapeutics, By Application
4.3.2.1 Prostate Cancer
4.3.2.2 Thyroid Cancer
4.3.2.3 Liver Cancer
4.3.2.4 Gep-Net Therapeutics
4.3.2.5 Metastatic Bone Cancer Therapeutics
4.3.2.6 Breast Cancer Therapeutics
4.3.2.7 Other Therapeutic Applications

5 Nuclear Medicine Global Market, By End-Users
5.1 Introduction
5.2 Hospital
5.3 Ambulator-Y Centers
5.4 Diagnostic Centers
5.5 Other End-Users

6 Stable Isotopes
6.1 Introduction
6.2 Market Analysis
6.2.1 Factors Influencing Market
6.2.2 Drivers And Opportunities
6.2.2.1 Increase In Research Activities (Pharmaceuticals And Biotechnology Sectors)
6.2.2.2 Increasing Applications
6.2.3 Restraints And Threats
6.2.3.1 High Cost Of Stable Isotopes
6.2.3.2 Stable Isotopes-Side Effects And Safety Issues
6.2.3.3 Stringent Regulations For Manufacturing And Use Of Stable Isotopes
6.3 Stable Isotopes Market, By Isotope
6.3.1 Carbon (C-13)
6.3.2 Deuterium (D2)
6.3.3 Oxygen (O-18)
6.3.4 Nitrogen (N-15)
6.3.5 Sulphur (S-32)
6.3.6 Others
6.4 Stable Isotopes Market, By Application
6.4.1 Introduction
6.4.2 Diagnostics And Therapy
6.4.3 Pharmaceuticals
6.4.4 Others
6.5 Stable Isotopes Market, By Geography
6.5.1 Introduction
6.5.2 North America
6.5.3 Europe
6.5.4 Asia-Pacific
6.5.5 Rest Of The World

7 Regional Analysis

8 Competitive Landscape
8.1 Introduction
8.2 Approvals And Agreements
8.3 Acquisition, Expansion And Collaboration
8.4 Others Developments

9 Major Player Profiles

Ablynx Nv
Abx Gmbh
Actinium Pharmaceuticals, Inc
Advanced Accelerator Applications
Advanced Medical Isotope Corporation
Affibody Ab
Algeta Asa
Aptuit
Areva Med
Arronax
Auspex Pharmaceuticals
Bard Medicals
Bavarian Nordic
Bayer Healthcare
Best Medical International, Inc
Bio Analytical Research Corporation Laboratories
Bio-Nucleonics,Inc
Bracco Diagnostics Incs
Btg International Ltd
Bv Cyclotron Vu
Cambridge Isotope Laboratories Inc.
Cardinal Health Inc.
Cellectar Biosciences
Centre For Probe Development And Commercialization
China Isotope Corporation
Clarity'S Pharmaceuticals
Coqui Pharmaceuticals
Cortecnet
Cp Medical
Digirad Corporation
Draximage Inc.
Eckert & Ziegler Strahlen
Eden Radioisotopes Llc
Eli Lilly & Co
Eurisotop
Fujifilm Corporation
Ge Healthcare
Huayi Isotopes Co
Iba Group
Ibt-Bebig
Idb Holland Bv
Immunomedics
Industrial Nuclear Company
International Isotopes Inc.
Invap S.E
Iso Ray Medical Inc
Iso Therapeutics Group, Llc
Iso-Analytical Ltd
Isoaid Llc
Isoflex Isotope
Isorad Ltd
Isotec Inc
Isotope Technologies Garching
Ithemba Labs
Joint Stock Company Isotope
Lantheus Medical Imaging Inc
Linde Group
Mallinckrodt Plc
Medi-Physics, Inc
Medical Isotopes, Inc
Mediso Medical Imaging Systems
Memorial Sloan Kettering Cancer Center
Navidea Biopharmaceuticals Inc
Nihon Medi Physics Co Ltd
Nordion Inc.
Northstar Medical Technologies
Ntp Radioisotopes Soc Ltd
Octreopharm Sciences Gmbh
Ostuka Pharmaceuticals Co Ltd
Pars Isotope
Peregrine Pharmaceuticals, Inc
Perkin Elmer
Perma-Fix Medical Sa
Petnet Solution
Philips Health Care
Positron Corporation
Radiomedix, Inc.
Rotem Medical
Royal Philips Electronics
Sanofi
Sercon Australia Pvt Ltd
Sercon Ltd
Shangai Research Institute Of Chemical Industry
Shine Medical Technologies, Inc
Siemens Healthcare
Sievert
Sirtex
Source Production And Equipment Company+F191
Spectrum Pharmaceuticals, Inc
Spepharm Ag
Stb Isotope Germany Gmbh
Sterigenics International
Steripet
Tayyo Nippon Sanso Corporation
Theragenics Corporation
Thermo Fisher Scientific
Toshiba Medical Systems Corporation
Tracerco
Trigon Biotechnology Inc
Urenco
Westinghouse Electric Company
Zevacor Molecular

For more information about this report visit https://www.researchandmarkets.com/research/7z5826/global_nuclear?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets